Skip to main content
. 2020 Oct 1:ciaa1187. doi: 10.1093/cid/ciaa1187

Table 4.

Univariate and Multivariable Analysis with Cox Proportional Hazard Model on Factors Associated with Primary Endpoint (A Composite Endpoint of Intensive Care Unit Admission, Use of Invasive Mechanical Ventilation, and Death) Among COVID-19 Patients After Multiple Imputation

Parameters Univariate Analysis Multivariable Analysis
HR (95% CI) P Value aHR (95% CI) P Value
Age, y 1.05 (1.04–1.07) <.0001 1.02 (1.00–1.04) .040
Male 1.63 (.94–2.85) .084
Hemoglobin 0.88 (.74–1.03) .12
White blood cell 1.14 (1.02–1.27) .023
Platelet 0.99 (.99–1.00) .0065 0.995 (.991–1.000) .031
Alanine aminotransferase 1.01 (1.00–1.02) .0030
Albumin 0.87 (.83–.90) <.0001
Total bilirubin 1.02 (.98–1.07) .31
International normalized ratio 2.14 (.46–9.97) .33
Creatinine 1.02 (1.01–1.03) .00020
C-reactive protein 1.14 (1.11–1.17) <.0001 1.07 (1.02–1.12) .0065
Lactate dehydrogenase (per 100 U/L) 2.17 (1.34–3.52) .0031 1.48 (1.15–1.91) .0027
Neutrophil-to-lymphocyte ratio 1.24 (1.18–1.30) <.0001
Circulatory system disease 5.62 (3.31–9.54) <.0001
Digestive system disease 3.48 (1.58–7.70) .0020
Diabetes mellitus 10.06 (5.90–17.15) <.0001 3.21 (1.72–6.00) .00026
Malignant tumor 2.88 (.70–11.83) .14
Nervous system disease 1.41 (.20–10.19) .73
Respiratory disease 5.90 (1.84–18.89) .0028
Chronic kidney disease 5.47 (1.33–22.46) .018
Bacterial or viral coinfection 1.41 (.44–4.52) .56
Hypoxia during follow-up 2.22 (.95–5.17) .066
Lopinavir-ritonavir during follow-up 0.95 (.56–1.62) .85
Ribavirin during follow-up 1.11 (.65–1.88) .71
Interferon beta during follow-up 1.14 (.66–1.99) .64
Steroid during follow-up 4.02 (1.90–8.51) .0003

Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; COVID-19, coronavirus disease 2019; HR, hazard ratio.